Editas Medicine (EDIT) Stock Forecast & Price Target

Editas Medicine is viewed positively because EDIT-401 could offer a differentiated, one-time LDLR upregulation strategy with preclinical reductions of >90% in LDL-C and >70% in ApoB, plus emerging evidence for lowering Lp(a) as well, which may address multiple ASCVD risk drivers at once. The approach is supported by human genetic validation and a favorable clinical backdrop from the 2026 ACC/AHA Dyslipidemia Guideline, which reinforces explicit LDL-C goals and universal Lp(a) screening, potentially expanding demand for potent lipid-lowering therapies. Financially, the company had $123.6 million in cash and equivalents as of 31 March 2026, with guidance for runway into 3Q27, giving it time to advance preclinical work and a first-in-human trial later this year.

Editas Medicine is burdened by a high-risk clinical and regulatory profile, as first-in-human data for EDIT-401 and the dual guideRNA system remain limited, leaving safety, off-target editing, and efficacy translation from animal models to patients unresolved. The company also faces meaningful commercial uncertainty because demand for gene editing treatments in HeFH/ASCVD has not been proven, while reimbursement, competition, and the need to build sales and medical infrastructure could constrain adoption. Financially, the stock’s downside case is reinforced by only $1.02/share in net cash, $0.56 NPV/share from other pipeline and CGEF factors, and a likely need for additional capital that could dilute shareholders before profitability.